Recent Updates
Recently added Catalysts
NVO Positive Sentiment

Novo Nordisk A/S - share repurchase programme

Key Takeaway: Novo Nordisk A/S announced a share repurchase programme on 6 May 2026, aiming to buy back up to DKK 15 billion in shares over 12 months. As of 13 November 2026, the company has repurchased 43,734,179 B shares at an average price of DKK 277.08 per share. The initiative reflects Novo Nordisk's commitment to enhancing shareholder value.

Market Sentiment Analysis

POSITIVE FACTORS

  • Novo Nordisk initiated a significant share repurchase programme.
  • The company plans to repurchase up to DKK 15 billion in shares.
  • They have already repurchased over 43 million B shares.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
2.8%
average across 15 past catalysts
Lead asset
IcoSema
Phase 3 · Type 2 Diabetes

Full Press Release Details

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 16 November 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.
Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.
Since the announcement 9 November, the following transactions have been made:
Number of B shares Average purchase price Transaction value, DKK
Accumulated, last announcement 27,845,000 8,008,013,722
9 November 2026 230,000 273.19 62,833,589
10 November 2026 225,000 273.53 61,543,729
11 November 2026 225,000 272.61 61,336,770
12 November 2026 225,000 276.39 62,188,860
13 November 2026 225,000 276.25 62,156,610
Accumulated under the programme 28,975,000 8,318,073,280
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
Transactions related to Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 129,745 B shares in the period from from 9 November 2026 to 13 November 2026 The shares in these transactions were not part of the Safe Harbour repurchase programme. With the transactions stated above, Novo Nordisk owns a total of 57,645,131 B shares of DKK 0.10 as treasury shares, corresponding to 1.3% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 13 November 2026, Novo Nordisk has since 4 February 2026 repurchased a total 43,734,179 B shares at an average share price of DKK 277.08 per B share equal to a transaction value of DKK 12,118,073,269.
Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 66,500 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube.

Contacts for further information

Novo Nordisk Media:
Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com Liz Skrbkova (US) +1 609 917 0632 USMediaRelations@novonordisk.com
Novo Nordisk Investors:
Michael Novod +45 3075 6050 nvno@novonordisk.com Sina Meyer +45 3079 6656 azey@novonordisk.com
Max Ung +45 3077 6414 mxun@novonordisk.com Christoffer Togo Solgaard-Tullin +45 3079 1471 cftu@novonordisk.com
Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com
Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com Alex Bruce (US) +1 640 230 0276 axeu@novonordisk.com
Company announcement No 68 / 2026

Frequently Asked Questions

What is the purpose of Novo Nordisk's share repurchase programme?

The programme aims to enhance shareholder value by repurchasing shares.

How much does Novo Nordisk plan to repurchase?

Novo Nordisk plans to repurchase up to DKK 15 billion in shares.

When did the share repurchase programme start?

The programme started on 6 May 2026.

How many B shares has Novo Nordisk repurchased so far?

As of 13 November 2026, 43,734,179 B shares have been repurchased.

Last updated: Nov 16, 2026